Listed by the USPTO as SCHLOOP, ALLISON ELIZABETH
Tech Center 1600 • Art Units: 1682 1683 1693
This examiner grants 63% of resolved cases
SCHLOOP, ALLISON ELIZABETH has 49 resolved cases and an allowance rate of 63.3%. The median time to allowance is 1460 days. Interviews correspond to a 47.6% lift in the allowance rate, making interview preparation a significant consideration in this record. The limited resolved-case volume means counsel should use the profile as a directional guide and test its relevance against the claims and office-action history of the application.
The listed companies are The Johns Hopkins University, 10x Genomics Inc., and California Institute of Technology. The listed firms are Fox Rothschild LLP - JHU, HODGSON RUSS LLP, and WILSON SONSINI GOODRICH & ROSATI. These entities identify the research and counsel experience represented in the available matters.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18405884 | METHODS AND COMPOSITIONS FOR IN SITU ANALYSIS OF VARIANT SEQUENCES | Non-Final OA | 10x Genomics, Inc. |
| 18280164 | NUCLEIC ACID DETECTION AND ANALYSIS SYSTEMS | Non-Final OA | The Johns Hopkins University |
| 17771772 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ESOPHAGEAL CANCER | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 17683246 | SAME-SAMPLE ANTIBIOTIC SUSCEPTIBILITY TEST AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | Non-Final OA | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 17760033 | COMPOSITIONS AND METHODS FOR RAPID RNA-ADENYLATION AND RNA SEQUENCING | Final Rejection | Cornell University |
| 18332359 | A MULTIPLEX CRISPR BASED ASSAY FOR THE SIMULTANEOUS DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE | Final Rejection | The Penn State Research Foundation |
| 18578523 | EFFICIENT DUPLEX SEQUENCING USING HIGH FIDELITY NEXT GENERATION SEQUENCING READS | Non-Final OA | University of Washington |
| 18361797 | SYSTEM FOR PERFORMING NUCLEIC ACID AMPLIFICATION ASSAYS | Final Rejection | GEN-PROBE INCORPORATED |
| 17995855 | ENDOGENOUS RETROVIRUSES FOR THE DETECTION, DIAGNOSIS, AND PROGNOSIS OF CANCER | Non-Final OA | SunnyBay BioTech, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.3% of resolved applications examined by Allison Elizabeth Schloop were allowed (49 resolved cases), compared with 41.5% across Art Unit 1682 over the last five years.
This examiner's interview lift is +47.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Allison Elizabeth Schloop took 1,460 days on average from filing to allowance.
Allison Elizabeth Schloop examines applications in Art Unit 1682 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
